37 related articles for article (PubMed ID: 8885123)
1. Insights into CYP2B6-mediated drug-drug interactions.
Hedrich WD; Hassan HE; Wang H
Acta Pharm Sin B; 2016 Sep; 6(5):413-425. PubMed ID: 27709010
[TBL] [Abstract][Full Text] [Related]
2. Bupropion: a review of its use in the management of major depressive disorder.
Dhillon S; Yang LP; Curran MP
Drugs; 2008; 68(5):653-89. PubMed ID: 18370448
[TBL] [Abstract][Full Text] [Related]
3. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.
Dwoskin LP; Rauhut AS; King-Pospisil KA; Bardo MT
CNS Drug Rev; 2006; 12(3-4):178-207. PubMed ID: 17227286
[TBL] [Abstract][Full Text] [Related]
4. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
Thuerauf N; Lunkenheimer J
Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice.
Wang JS; DeVane CL; Gibson BB; Donovan JL; Markowitz JS; Zhu HJ
Psychopharmacology (Berl); 2006 Jan; 183(4):490-9. PubMed ID: 16283256
[TBL] [Abstract][Full Text] [Related]
6. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.
Crone CC; Gabriel GM
Clin Pharmacokinet; 2004; 43(6):361-94. PubMed ID: 15086275
[TBL] [Abstract][Full Text] [Related]
7. Clinically significant drug interactions with antidepressants in the elderly.
Spina E; Scordo MG
Drugs Aging; 2002; 19(4):299-320. PubMed ID: 12038880
[TBL] [Abstract][Full Text] [Related]
8. Drug interactions with patient-controlled analgesia.
Lotsch J; Skarke C; Tegeder I; Geisslinger G
Clin Pharmacokinet; 2002; 41(1):31-57. PubMed ID: 11825096
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.
Rotzinger S; Bourin M; Akimoto Y; Coutts RT; Baker GB
Cell Mol Neurobiol; 1999 Aug; 19(4):427-42. PubMed ID: 10379419
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data.
Høiseth G; Haslemo T; Uthus LH; Molden E
Ther Drug Monit; 2015 Oct; 37(5):589-93. PubMed ID: 25565674
[TBL] [Abstract][Full Text] [Related]
11. Bupropion: pharmacology and therapeutic applications.
Foley KF; DeSanty KP; Kast RE
Expert Rev Neurother; 2006 Sep; 6(9):1249-65. PubMed ID: 17009913
[TBL] [Abstract][Full Text] [Related]
12. Bupropion plasma levels and CYP2D6 phenotype.
Pollock BG; Sweet RA; Kirshner M; Reynolds CF
Ther Drug Monit; 1996 Oct; 18(5):581-5. PubMed ID: 8885123
[TBL] [Abstract][Full Text] [Related]
13. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ
Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.
Teitelbaum AM; Flaker AM; Kharasch ED
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Apr; 1017-1018():101-113. PubMed ID: 26963497
[TBL] [Abstract][Full Text] [Related]
15. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
Jefferson JW; Pradko JF; Muir KT
Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
